secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silo Pharma, Inc. (SILO)
CIK:        0001514183
Form:       8-K
Filed at:   2024-06-27T23:59:59+00:00
Accession:  0001213900-24-056678
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silo Pharma amends license milestones with University of Maryland, Baltimore
----------------------------------------------------------------------------

- Fourth Amendment replaces Schedule C diligence milestones under the Master License Agreement.
- New milestones include completing in vitro peptide binding by March 2025 and preclinical studies by September 2025.
- IND filing for a Licensed Product due by February 2028; first commercial sale by February 2034.
- All other terms, including royalty rate and payment obligations, remain unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1514183/000121390024056678/0001213900-24-056678-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1514183/000121390024056678/ea0208662-8k_silo.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-056678

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer